Introduction
Benzodiazepines are one of the most commonly used drugs in Scotland. The most commonly prescribed benzodiazepine in Scotland is diazepam. In the financial year 2013-2014, diazepam was dispensed 891,005 times. The second most dispensed benzodiazepine was temazepam, followed by nitrazepam. These figures include repeat prescriptions as well as prescriptions writ-ten in hospital that were dispensed within the community but not prescriptions dispensed within hospitals (1) . Phenazepam was the first uncontrolled benzodiazepine to emerge on the UK recreational market; police seized phenazepam in white powder form in Scotland in October 2008. From 2008 to 2011, phenazepam was detected in blue pills seized in the UK; these pills often had markings that suggested they were being sold as diazepam (2) . Phenazepam was subsequently controlled in the UK in 2012 (3) . Phenazepam has been a prescribed drug in Russia since the 1970s for neurological disorders, epilepsy and alcohol withdrawal (4) .
Etizolam has been prescribed in Japan since 1983 for anxiety and used as a strong muscle relaxant. The drug was first reported to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in December 2011 after four blue tablets were seized from an individual in the UK who had purchased them online (5) . Etizolam has become increasingly popular rec-reationally in the UK and remains unscheduled. Etizolam abuse has been reported as a problem in Japan (6) .
Pyrazolam emerged on the online recreational market in 2012. Unlike phenazepam and etizolam, it is not marketed by any pharmaceutical company anywhere in the world; therefore, it is considered as the first designer benzodiazepine produced for the legal market. comparison was also prepared at 1 mg/mL in methanol. Blank blood and PBS buffer were fortified with oxazepam at concentra-tions of 0, 5, 10, 100 and 300 ng/mL, and these were used as cal-ibrators. These concentrations were chosen to cover a suitable range. Individual aliquots of blank blood were fortified with phe-nazepam, etizolam, pyrazolam, flubromazepam, diclazepam and delorazepam at the same concentrations. All fortified blood, cal-ibrators and controls were diluted 1 : 4 with PBS buffer.
Instrumentation
The Tecan Miniprep 75, Columbus plate washer and Sunrise plate reader (all manufactured by Tecan Group Ltd., Switzerland) were used for this study.
Immunoassay procedure
Every fortified blood sample was prepared in duplicate, and every sample was pipetted into two separate wells providing four results for each concentration. Ten microliters of calibra-tor, control or fortified blood were added into each appropri-ate well. The samples were added in the order of increasing concentration. The immunoassay was carried out according to the Immunalysis protocol (10) . The absorbance was mea-sured at 450 nm using the plate reader. The absorbance is in-versely proportional to the concentration of the drug. Sensitivity, precision and cross-reactivity data were provided by Immunalysis.
Results and discussion
In forensic toxicology, it is important to keep up with emerging drugs of abuse and be aware of the drugs that give us a positive response at the screening step. It is crucial that laboratory confir-mation methods are capable of matching the range of drugs that can be detected at the screening step in order for the screen to be a valuable test. This study found that these benzodiazepines do cross react with the Immunalysis ® Benzodiazepine ELISA kit (Table I) 
Case study
This case study describes the death of a 20-year-old male who had been diagnosed with a psychotic disorder. He had a history 
Conclusion
This study has illustrated that all six drugs tested have good crossreactivity with the Immunalysis ® Benzodiazepine ELISA kit. The benzodiazepine drug group is vast and has the potential for many uncontrolled drugs to be added to the legal market. As the prevalence of these drugs is unknown, it is critical that confirmatory toxicological methods expand to include the newer emerging drugs in order to stay relevant. Including these new drugs in rou-tine analysis will allow the prevalence of this drugs to be monitored.
